MedTrace Logo

SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas

NCT02301039 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2020-09-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the efficacy of pembrolizumab in patients with advanced sarcomas.

Conditions

  • Soft Tissue Sarcoma
  • Bone Sarcoma

Interventions

DRUG

Pembrolizumab

Sponsors & Collaborators

Principal Investigators

  • Hussein Tawbi, MD, PhD · The University of Texas MD Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2020-07-01
Completion
2020-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02301039 on ClinicalTrials.gov